SCHEMBL1696247

SCHEMBL1696247

CCNc1cc(CN)ccc1CC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 3/20 0.41
CSNK2A2 P19784 1/20 0.41
CSNK2B P67870 1/20 0.41
CSNK2A3 Q8NEV1 1/20 0.41
AOC1 P19801 1/20 0.41
AOC3 Q16853 1/20 0.41
HDAC8 Q9BY41 1/20 0.37
GAA P10253 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
GFER P55789 1/20 0.37
PLEC Q15149 1/20 0.37
PSIP1 O75475 1/20 0.36
BACE1 P56817 1/20 0.36
LOXL2 Q9Y4K0 2/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10541651 0.86 HDAC8 (0.40) AOC1AOC3HDAC8GAAKDM4E
SCHEMBL15676709 0.79 CYP3A4 (0.56) CSNK2A1CSNK2A2CSNK2BCSNK2A3AOC1
SCHEMBL18901387 0.78 LOXL2 (0.39) CSNK2A1AOC1AOC3HDAC8GAA
SCHEMBL28135906 0.77 CSNK2A1 (0.39) CSNK2A1CSNK2A2CSNK2BCSNK2A3GAA
SCHEMBL28047555 0.76 ALDH1A1 (0.41) CSNK2A1CSNK2A2CSNK2BCSNK2A3GAA
SCHEMBL1696358 0.76 CSNK2A1 (0.49) CSNK2A1CSNK2A2CSNK2BCSNK2A3GAA
SCHEMBL1690359 0.75 AOC1 (0.36) CSNK2A1CSNK2A2CSNK2BCSNK2A3AOC1
SCHEMBL15353756 0.75 CYP3A4 (0.33) HDAC8CYP3A4TSHRRECQL
SCHEMBL18387183 0.75 CYP1A2 (0.42) HDAC8GAAKDM4EALDH1A1MAPT
SCHEMBL1829609 0.75 HDAC8 (0.40) HDAC8ALDH1A1MAPTHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088758-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-04-12 US disclosed
US-7453002-B2 thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088758-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS F12, F11, F5 CSNK2A1 1076/4885CSNK2A2 1333/4885CSNK2B 1628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.